VGNX -- Variagenics, Inc. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VGNX -- Variagenics, Inc.

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who wrote (132)	4/1/2002 7:22:55 PM
From: scaram(o)uche	of 269

The 10-K today is April Fools, VGNX style. In the pharmaceuticals/biotechnology sector, we have entered into Variagenic® Impact Program collaborations with Amgen Inc., Boehringer Ingelheim Pharmaceuticals, Inc. and Isis Pharmaceuticals, Inc. In August 2000, we signed a collaborative agreement with Boehringer Ingelheim to utilize our VIP capabilities in the development of a new therapeutic candidate by Boehringer Ingelheim. The goal of the program is to identify genetic markers predictive of therapeutic response, and to use this information in drug development as well as in the development of a diagnostic test. In 2001, we delivered our marker discovery report and we are presently in the final stage of assay development. We entered into VIP agreements with Isis and Amgen in 2000 and 2001, respectively. We have delivered our marker discovery reports under these agreements. At H&Q, Crouch clearly said that the B. Ingelheim assay had transitioned into clinical testing. I believe that I saw or heard it somewhere else recently? Those statements may not be incompatible, but.... if they aren't, I doubt that any non-employees are in on the verbal secret handshake.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next